Cramer says Agios Pharmaceuticals is unique and different and yesterday its experimental cancer drug delivered some strong results in patients with advanced leukemia.
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
Inflation picked up in October due to higher prices that U.S. companies received for new model cars, beef, pork, pharmaceuticals and electric power.
Goldman Sachs cemented its status as the number one financial adviser for global mergers & acquisitions volume, at $873 billion year-to-date, according to Thomson Reuters.
TheStreet's Jim Cramer says Zoetis' $500 million buyback is a defense tactic to prevent a takeover, while shares of GoPro are headed higher despite its secondary offering.
Shares of Teva remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.
No big moves on Wall Street but the S&P 500 still managed to close at a record high Monday.
Actavis is finalizing a $66 billion deal to buy Botox-maker Allergan for a combination of cash and stock.
Shares of Teva Pharmaceuticals remain relatively inexpensive despite the stock's sharp move higher this year, said Andrew Ver Planck, portfolio manager for the MainStay International Opportunities Fund.
From Keystone to pharmaceuticals, industrials and energy, the Republican wins in midterm elections create real opportunities investors can take advantage of.
Stocks are little changed in midday trading Monday after opening slightly lower on Japan slipping into recession.
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
Pfizer is set to pay Merck $850 million for the rights to a new cancer drug.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV